Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TLR4 | O00206 | 12/20 | 0.46 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763047 | 1.00 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12762965 | 1.00 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12560694 | 1.00 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12560697 | 0.94 | TLR4 (0.46) | MAPK1TLR4LY96 | |
| SCHEMBL12560728 | 0.94 | TLR4 (0.46) | MAPK1TLR4LY96 | |
| SCHEMBL12762967 | 0.94 | TLR4 (0.46) | MAPK1TLR4LY96 | |
| SCHEMBL12560681 | 0.94 | TLR4 (0.46) | MAPK1TLR4LY96 | |
| SCHEMBL13296765 | 0.91 | MAPK1 (0.42) | MAPK1TLR4LY96 | |
| SCHEMBL13296777 | 0.91 | MAPK1 (0.42) | MAPK1TLR4LY96 | |
| SCHEMBL12371591 | 0.91 | MAPK1 (0.42) | MAPK1TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | MAPK1 2123/4885TLR4 24/4885LY96 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.